Among adults aged 18-49 with first-time pulmonary embolism, 30-day mortality declined from 416.6 to 262.4 per 1000 person-years between 2006-2008 and 2021-2023 (aRR 0.89; 95% CI 0.84-0.94).
Observational (n=18,173)
Yes
In young adults with first-time pulmonary embolism, 30-day mortality declined from 2006 to 2015 but has since plateaued, while longer-term mortality remained stable and is primarily driven by comorbidities such as cancer.
Effect estimate: aRR 0.89 (95% CI 0.84-0.94)
Absolute Event Rate: 262.4% vs 416.6%
BACKGROUND: Pulmonary embolism (PE) carries substantial mortality, but recent mortality trends and underlying causes of death among young adults during the last 2 decades remain insufficiently studied. OBJECTIVES: This study investigated time trends in all-cause mortality within 30 days, 31 to 365 days, and 1 to 3 years among patients with PE aged 18 to 49 years. Secondary aims included examining mortality trends in subgroups and cause-specific mortality. METHODS: This is a nationwide Swedish register study of patients aged 18 to 49 years with first-time PE, from 2006 to 2023. Mortality rates and temporal trends with age- and sex-adjusted rate ratios (aRRs) per 3-year interval were calculated using Poisson regression, overall and stratified by cancer, sex, age group, and pregnancy- and postpartum-related PE. RESULTS: Among 18 173 patients, 30-day mortality declined from 416.6 per 1000 person-years in 2006-2008 to 262.4 in 2021-2023 (aRR, 0.89; 95% CI, 0.84-0.94) but plateaued from 2015 to 2017. Mortality at 31 to 365 days (58.6-44.7 per 1000 person-years) and 1 to 3 years (14.7-14.2) remained stable over time. Among 1-year survivors, mortality declined among cancer patients (aRR, 0.84; 95% CI, 0.76-0.92). Venous thromboembolism was the leading cause of 30-day mortality among cancer-free patients. After 30 days, cancer was the leading cause of death, including among individuals without cancer at baseline. CONCLUSION: The 30-day mortality rate after first-time PE declined early in the study period, but plateaued from the period 2015-2017 onward. Mortality beyond 30 days remained stable and was only marginally attributable to venous thromboembolism as underlying cause, underscoring the importance of comorbidity management in postacute PE care.
Philipson et al. (Sun,) conducted a observational in first-time pulmonary embolism (n=18,173). Time period (2021-2023) vs. Time period (2006-2008) was evaluated on All-cause mortality within 30 days (aRR 0.89, 95% CI 0.84-0.94). Among adults aged 18-49 with first-time pulmonary embolism, 30-day mortality declined from 416.6 to 262.4 per 1000 person-years between 2006-2008 and 2021-2023 (aRR 0.89; 95% CI 0.84-0.94).